Genomill and iCAN, the leading cancer research initiative in Finland, have signed a partnership with the goal of enhancing the identification of minute traces of tumor DNA across a vast collection of biobank samples.
This collaboration represents a significant step forward in the field of cancer research and personalized medicine. By combining their respective expertise, the two organizations aim to contribute to the global efforts to combat cancer and improve patient care.
Genomill, an innovative company specializing in precise diagnostics, introduces its advanced Geno1® platform as part of the collaboration. Genomill’s exclusive and patented platform allows for rapid, affordable, and precise examination of cell-free tumor DNA derived from blood plasma samples.
This partnership takes advantage of the vast collection of patient samples and comprehensive molecular profiling data found in the iCAN Flagship Project. iCAN is a leader in advancing precision cancer medicine by connecting tumor profiling data with extensive health information from over 10,000 patients.
By combining this valuable resource with Genomill’s state-of-the-art genomic analysis platform, the partnership aims to gain deeper insights into the molecular characteristics of various cancer types and improve the accuracy of cancer detection.
“We are excited to collaborate with iCAN to validate and further develop our proprietary and patented Geno1® platform,” noted Kalle Koskinen, CEO of Genomill. “We expect this partnership will push the envelope in leveraging accessible and actionable liquid biopsies on a global scale, especially with a focus on Minimal Residual Disease (MRD) and Treatment (Tx) Selection. Genomill’s mission is to lower the barriers to global adoption of liquid biopsies in precision diagnostics,” he noted.
The iCAN Flagship Project offers an exceptional opportunity to assess the platform’s effectiveness in detecting cancer across various disease stages, as well as in different cancer types.
“We are thrilled to investigate the sensitivity of this novel technology to detect circulating cell-free tumour DNA initially in colorectal and lung cancer,” said Tomi Mäkelä, iCAN Executive Officer. “The partnership with Genomill aligns with iCAN’s mission to leverage the iCAN Discovery Platform for contributions to diagnostic development and for meeting the evolving needs of cancer patients.”